目的 观察参附注射液联合低分子肝素钙治疗慢性肺原性心脏病(以下简称肺心痛)急性发作的临床疗效.方法 将162例慢性肺心病急性发作患者随机分为2组,对照组82例予西医常规治疗,治疗组80例加参附注射液联合低分子肝素钙治疗,均连续治疗10 d,检测2组治疗前后动脉血气分析指标及血液流变学指标变化情况,统计临床疗效.结果 治疗组总有效率92.5％,对照组总有效率75.61％,2组总有效率比较差异有统计学意义(P＜0.01),治疗组临床疗效优于对照组.治疗组治疗后动脉血气分析指标pH值、氧分压[p(02)]、二氧化碳分压[p(C02)]及血液流变学指标与本组治疗前比较均明显改善(P ＜0.05,P＜0.01),且治疗组改善优于对照组(P ＜0.05,P＜0.01).结论 参附注射液联合低分子肝素钙可明显改善慢性肺心病急性发作患者的肺通气功能及血液黏稠度,临床疗效确切.%Objective To investigate the clinical efficacy of Shenfu injection combined with low molecular weight heparin calcium in the treatment of acute exacerbation of chronic pulmonary heart disease. Methods 162 patients with acute exacerbation of chronic pulmonary heart disease were randomly divided into two groups. Control group (n =82) received conventional Western medicine therapy. Treatment group (n =80) received Shenfu injection combined with low molecular weight heparin calcium. Patients in two groups were continuously treated for 10 days. The changes of arterial blood gas analysis indicators and hemorheology were detected. Results The total effective rate in treatment group (92.5%) was higher than that in control group (75.61%, P < 0. 05). Arterial blood gas analysis indicators including pH, p (O2) , p (CO2) and hemorheology after treatment were significantly improved as compared with those before treatment in treatment group (P < 0.05, P < 0.01). The improvement in treatment group was superior to that in control group ( P < 0. 05 , P < 0. 01 ) . Conclusion Shenfu injection combined with low molecular weight heparin calcium can significantly improve pulmonary ventilation function and blood viscosity in patients with a-cute exacerbation of chronic pulmonary heart disease.
展开▼
